fludarabine + mitoxantrone + rituximab

The combination of fludarabine, mitoxantrone, and rituximab (often abbreviated as FMR) is a chemoimmunotherapy regimen used primarily for treating hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma. ## Description Fludarabine + mitoxantrone + rituximab (FMR) is a combination chemoimmunotherapy regimen that brings together three distinct mechanisms of action to treat hematological malignancies. This regimen combines: 1. **Fludarabine**: A purine analog antimetabolite that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase, leading to cell death in both dividing and resting lymphocytes. 2. **Mitoxantrone**: An anthracenedione antineoplastic agent that intercalates with DNA, causing cross-links and strand breaks, and inhibits topoisomerase II, disrupting DNA repair. 3. **Rituximab**: A chimeric monoclonal antibody targeting CD20 antigen on B-lymphocytes, causing cell death through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct induction of apoptosis. Clinical trials have shown this combination to be highly effective in previously untreated chronic lymphocytic leukemia (CLL), with response rates up to 93% and complete response rates of 82%. The regimen has demonstrated effectiveness in achieving minimal residual disease (MRD)-negative complete responses in a significant proportion of patients. FMR has also shown promise in treating relapsed mantle cell lymphoma and follicular lymphoma.

Other names

Fludarabine-mitoxantrone-rituximab